Jennifer Brown
Gynecologic Oncology · Humble, TXNPI 1407083645
Payments from drug & device makers
What this record shows
This record is dominated by education: $8,000 of the $10,257 with a category attached, or 78.0%. Intuitive Surgical accounts for 81.3% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $8,780 and has fallen 89.1% since, to $956 in 2025.
Across 74 payments — averaging $138.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$8K
- Eisai Inc.$356
- Tempus AI, Inc$268
- Aroa Biosurgery Incorporated$264
- Genmab U.S., Inc.$177
- Merck$106
- plus $751 from 21 others
What the payments were for
- Food & beverage$2,25722%
- Education$8,00078%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $8,335 |
| Eisai Inc. | 12 | $356 |
| Tempus AI, Inc | 12 | $268 |
| Aroa Biosurgery Incorporated | 2 | $264 |
| Genmab U.S., Inc. | 5 | $177 |
| Merck | 5 | $106 |
| AbbVie | 4 | $102 |
| AstraZeneca | 3 | $77 |
| Johnson & Johnson(2 entities) | 3 | $73 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Bayer | 2 | $56 |
| Medtronic | 1 | $48 |
| Novo Nordisk | 2 | $34 |
| Sobi, Inc | 1 | $34 |
| Boston Scientific | 1 | $29 |
| Corcept Therapeutics | 1 | $28 |
| Janssen Scientific Affairs, LLC | 1 | $26 |
| Smith+Nephew | 1 | $24 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| Pfizer | 1 | $19 |
| Coopersurgical, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Amgen | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$8,300
- LENVIMA$122
How this compares
$10,257 in reported general payments places this provider in the 70th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZejulaNiraparib Tosylate | 23 | $390,096 |
| EliquisApixaban | 19 | $13,749 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 90 | $1,383 |
| Dexamethasone | 56 | $843 |
| Megestrol Acetate | 12 | $727 |
| Clobetasol Propionate | 16 | $722 |
| Estradiol | 17 | $621 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 35 | $498 |
| Olanzapine | 42 | $477 |
| Pregabalin | 21 | $470 |
| Gabapentin | 50 | $377 |
| Anastrozole | 11 | $220 |
| Metronidazole | 24 | $200 |
| Fluconazole | 16 | $173 |
| Prochlorperazine Maleate | 15 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $13,74919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in Humble
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
- Michael FrumovitzHouston$156K
- Eugene ToyEl Paso$138K
- Aparna KamatHouston$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.